Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
- Authors
- Park, Inkeun; Choi, Seung Joon; Kim, Young Saing; Ahn, Hee Kyung; Hong, Junshik; Sym, Sun Jin; Park, Jinny; Cho, Eun Kyung; Lee, Jae Hoon; Shin, Yong Ju; Shin, Dong Bok
- Issue Date
- Oct-2016
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Pancreatic neoplasms; Gemcitabine; Drug therapy; Sarcopenia; Prognosis
- Citation
- CANCER RESEARCH AND TREATMENT, v.48, no.4, pp.1264 - 1273
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 48
- Number
- 4
- Start Page
- 1264
- End Page
- 1273
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7832
- DOI
- 10.4143/crt.2015.250
- ISSN
- 1598-2998
- Abstract
- Purpose The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinico-laboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. Results A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic diease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.86; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7832)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.